Application of a policy framework for the public funding of drugs for rare diseases

Journal of General Internal Medicine

Volumn 29, Issue SUPPL. 3, 2014, Pages

  Winquist, Eric ^a   Coyle, Doug ^b   Clarke, Joe T R ^c,d   Evans, Gerald A ^e   Seager, Christine ^f   Chan, Winnie ^f   Martin, Janet ^a  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

^f ONTARIO MINISTRY OF HEALTH AND LONG TERM CARE   (Canada)

Author keywords

cost effectiveness; drug reimbursement; rare diseases

Indexed keywords

COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HUMAN; ONTARIO; ORGANIZATION AND MANAGEMENT; RARE DISEASES; REIMBURSEMENT; RETROSPECTIVE STUDY;

COST-BENEFIT ANALYSIS; DRUG COSTS; FINANCIAL SUPPORT; HEALTH POLICY; HUMANS; ONTARIO; RARE DISEASES; REIMBURSEMENT MECHANISMS; RETROSPECTIVE STUDIES;

EID: 84905915127     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-014-2885-y     Document Type: Article

References (7)

1. Daniels N, Sabin J. Setting limits fairly: can we learn to share medical resources. Oxford, UK: Oxford University Press; 2002.
2. Cookson R. Can the NICE "End-of-Life Premium" be given a coherent ethical justification? J Health Politics. Policy Law. 2013;38(6):1131-50.
3. Drugs for Rare Diseases: Evolving Trends in Regulatory and Health Technology Assessment Perspectives. Canadian Agency for Drugs and Technologies in Health, October 2013. Available at: http://www.cadth.ca/media/pdf/ES0281- RareDiseaseDrugs-es-e.pdf. Accessed March 20, 2014.
4. Idursulfase Committee to Evaluation Drugs (CED) Recommendations and Reasons (September 2009). Available at: http://www.health.gov.on.ca/en/pro/ programs/drugs/ced/pdf/idursulfase.pdf. Accessed March 20, 2014.
5. How Drugs Are Considered: Funding Decisions. Drugs For Rare Diseases. Available at: http://www.health.gov.on.ca/en/pro/programs/drugs/how-drugs- approv/review-rare-diseases.aspx. Accessed March 20, 2014.
6. Winquist E, Bell CM, Clarke JT, Evans G, Martin J, Sabharwal M, Gadhok A, Stevenson H, Coyle D. An evaluation framework for funding drugs for rare diseases. Value Health. 2012;15(6):982-6.
7. Coyle D, Bell CM, Clarke JTR, Evans G, Gadhok A, Martin J, Sabharwal M, Winquist E. Application of operations research to funding decisions for treatments with rare disease. In: Zaric GS, ed. Operations Research and Health Care Policy, International Series in Operations Research & Management Science 190. New York: Springer Science & Business Media; 2013:281-94.